Over the past few years, there has been an increasing discussion about the potential cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs)
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in T2D patients and is the largest contributor of direct and indirect costs of diabetes 1
Yet those supply-chain issues proved short-lived in comparison to current onesover the vast majority of the last year-and-a-half, Danish drugmakers have once again faced a persistent lack of key inputs that is holding back production
Reduced glutathione is important for cell health and liver function
Add in the lack of regulation, potential purity issues, and unknown long-term safety profile, and you have a compound that demands informed decision-making
Previously, many of our campaigns relied mainly on discounts